Recombinant fusion toxins for cancer treatment
- 1 December 2002
- journal article
- Published by Informa UK Limited in Expert Opinion on Biological Therapy
- Vol. 2 (8), 785-791
- https://doi.org/10.1517/14712598.2.8.785
Abstract
(2002). Recombinant fusion toxins for cancer treatment. Expert Opinion on Biological Therapy: Vol. 2, No. 8, pp. 785-791. doi: 10.1517/14712598.2.8.785This publication has 54 references indexed in Scilit:
- Potent and specific antitumor effects of an anti-CD22–targeted cytotoxic ribonuclease: potential for the treatment of non-Hodgkin lymphomaBlood, 2001
- Prevention of graft-versus-host disease (GVHD) by elimination of recipient-reactive donor T cells with recombinant toxins that target the interleukin 2 (IL-2) receptorBone Marrow Transplantation, 1999
- Human neurological cancer cells express interleukin‐4 (IL‐4) receptors which are targets for the toxic effects of IL4‐pseudomonas exotoxin chimeric proteinInternational Journal of Cancer, 1994
- Stabilization of the Fv fragments in recombinant immunotoxins by disulfide bonds engineered into conserved framework regionsBiochemistry, 1994
- Human Renal Cell Carcinoma Cells Are Sensitive to the Cytotoxic Effect of a Chimeric Protein Composed of Human Interleukin-4 and Pseudomonas ExotoxinCellular Immunology, 1994
- Single-chain immunotoxin fusions between anti-tac and Pseudomonas exotoxin: Relative importance of the two toxin disulfide bondsBioconjugate Chemistry, 1993
- Interleukin‐4 induces proliferation of adult T‐cell leukemia cellsEuropean Journal of Haematology, 1993
- A proper amino terminus of diphtheria toxin is important for cytotoxicityBiochemical and Biophysical Research Communications, 1991
- Functional domains of pseudomonas exotoxin identified by deletion analysis of the gene expressed in E. coliCell, 1987
- Reconstitution of Diphtheria Toxin from Two Nontoxic Cross-Reacting Mutant ProteinsScience, 1972